BFR (bendamustine, fludarabine, and rituximab) allogeneic conditioning for chronic lymphocytic leukemia/lymphoma: Reduced myelosuppression and GVHD

Blood

Volumn 124, Issue 14, 2014, Pages 2306-2312

  Khouri, Issa F ^a   Wei, Wei ^a   Korbling, Martin ^a   Turturro, Francesco ^a   Ahmed, Sairah ^a   Alousi, Amin ^a   Anderlini, Paolo ^a   Ciurea, Stefan ^a   Jabbour, Elias ^a   Oran, Betul ^a   Popat, Uday R ^a   Rondon, Gabriela ^a   Bassett, Roland L ^a   Gulbis, Alison ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENDAMUSTINE; FLUDARABINE; METHOTREXATE; RITUXIMAB; TACROLIMUS; THYMOCYTE ANTIBODY; CHLORMETHINE DERIVATIVE; DRUG COMBINATION; MONOCLONAL ANTIBODY; VIDARABINE;

ADULT; AGED; ALOPECIA; BONE MARROW SUPPRESSION; CANCER PATIENT; CANCER RECURRENCE; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CONFERENCE PAPER; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; GRAFT VERSUS HOST REACTION; HUMAN; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; NAUSEA AND VOMITING; NEPHROTOXICITY; NEUTROPENIA; NONMYELOABLATIVE CONDITIONING; ORAL MUCOSITIS; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; TREATMENT OUTCOME; UNRELATED DONORS; VEIN OCCLUSION; ALLOTRANSPLANTATION; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; DRUG COMBINATION; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PROCEDURES; RECURRENT DISEASE;

ADULT; AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; COMBINED MODALITY THERAPY; DRUG COMBINATIONS; FEMALE; GRAFT VS HOST DISEASE; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOMA; MALE; MIDDLE AGED; NITROGEN MUSTARD COMPOUNDS; RECURRENCE; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; VIDARABINE;

EID: 84907683729     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-07-587519     Document Type: Conference Paper

References (29)

1. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large- B-cell lymphoma. N Engl J Med. 2002;346(4): 235-242.
2. van Oers MHJ, Van Glabbeke M, Giurgea L, et al. Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: longterm outcome of the EORTC 20981 phase III randomized intergroup study. J Clin Oncol. 2010; 28(17):2853-2858.
3. Advani RH, Buggy JJ, Sharman JP, et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol. 2013; 31(1):88-94.
4. Peniket AJ, Ruiz de Elvira MC, Taghipour G, et al; European Bone Marrow Transplantation (EBMT) Lymphoma Registry. An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation. Bone Marrow Transplant. 2003; 31(8):667-678.
5. Tam CS, Bassett R, Ledesma C, et al. Mature results of the M. D. Anderson Cancer Center riskadapted transplantation strategy in mantle cell lymphoma. Blood. 2009;113(18):4144-4152.
6. Khouri IF, Champlin RE. Nonmyeloablative allogeneic stem cell transplantation for nonhodgkin lymphoma. Cancer J. 2012;18(5): 457-462.
7. Rezvani AR, Storer B, Maris M, et al. Nonmyeloablative allogeneic hematopoietic cell transplantation in relapsed, refractory, and transformed indolent non-Hodgkin's lymphoma. J Clin Oncol. 2008;26(2):211-217.
8. Sorror ML, Storer BE, Sandmaier BM, et al. Fiveyear follow-up of patients with advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. J Clin Oncol. 2008;26(30):4912-4920.
9. Khouri IF, Bassett R, Poindexter N, et al. Nonmyeloablative allogeneic stem cell transplantation in relapsed/refractory chronic lymphocytic leukemia: long-term follow-up, prognostic factors, and effect of human leukocyte histocompatibility antigen subtype on outcome. Cancer. 2011;117(20):4679-4688.
10. Khouri IF, Saliba RM, Erwin WD, et al. Nonmyeloablative allogeneic transplantation with or without 90yttrium ibritumomab tiuxetan is potentially curative for relapsed follicular lymphoma: 12-year results. Blood. 2012;119(26): 6373-6378.
11. Ferrara JLM, Levine JE, Reddy P, Holler E. Graftversus- host disease. Lancet. 2009;373(9674): 1550-1561.
12. Cheson BD, Rummel MJ. Bendamustine: rebirth of an old drug. J Clin Oncol. 2009;27(9): 1492-1501.
13. Leoni LM, Bailey B, Reifert J, et al. Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents. Clin Cancer Res. 2008; 14(1):309-317.
14. Rummel MJ, Al-Batran SE, Kim SZ, et al. Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma. J Clin Oncol. 2005;23(15):3383-3389.
15. Fischer K, Cramer P, Busch R, et al. Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol. 2012;30(26): 3209-3216.
16. Damaj G, Gressin R, Bouabdallah K, et al. Results from a prospective, open-label, phase II trial of bendamustine in refractory or relapsed T-cell lymphomas: the BENTLY trial. J Clin Oncol. 2013;31(1):104-110.
17. Ohmachi K, Niitsu N, Uchida T, et al. Multicenter phase II study of bendamustine plus rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol. 2013;31(17): 2103-2109.
18. Rummel MJ, Niederle N, Maschmeyer G, et al; Study group indolent Lymphomas (StiL). Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an openlabel, multicentre, randomised, phase 3 noninferiority trial. Lancet. 2013;381(9873): 1203-1210.
19. Visani G, Malerba L, Stefani PM, et al. BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant/relapsed lymphoma patients. Blood. 2011; 118(12):3419-3425.
20. O'Quigley J, Pepe M, Fisher L. Continual reassessment method: a practical design for phase 1 clinical trials in cancer. Biometrics. 1990; 46(1):33-48.
21. Cheson BD, Pfistner B, Juweid ME, et al; International Harmonization Project on Lymphoma. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25(5): 579-586.
22. Hallek M, Cheson BD, Catovsky D, et al; International Workshop on Chronic Lymphocytic Leukemia. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008;111(12):5446-5456.
23. Przepiorka D, Weisdorf D, Martin P, et al. 1994 consensus conference on acute GVHD grading. Bone Marrow Transplant. 1995;15(6):825-828.
24. Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant. 2005;11(12):945-956.
25. Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat. 1988;16:1141-1154.
26. Gooley TA, Chien JW, Pergam SA, et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med. 2010;363(22): 2091-2101.
27. Storb R, Gyurkocza B, Storer BE, et al. Graftversus- host disease and graft-versus-tumor effects after allogeneic hematopoietic cell transplantation. J Clin Oncol. 2013;31(12): 1530-1538.
28. Reshef R, Luger SM, Hexner EO, et al. Blockade of lymphocyte chemotaxis in visceral graft-versushost disease. N Engl J Med. 2012;367(2): 135-145.
29. Khouri IF, Saliba R, Challagundla P, et al. Bfr (bendamustine, fludarabine, rituximab) vs. FCR nonmyeloablative allogeneic conditioning in relapsed/refractory chronic lymphocytic leukemia (CLL): outcome results including minimal residual disease analysis [abstract]. Blood. 2013;122:541a.